JP2014012683A5 - - Google Patents

Download PDF

Info

Publication number
JP2014012683A5
JP2014012683A5 JP2013166370A JP2013166370A JP2014012683A5 JP 2014012683 A5 JP2014012683 A5 JP 2014012683A5 JP 2013166370 A JP2013166370 A JP 2013166370A JP 2013166370 A JP2013166370 A JP 2013166370A JP 2014012683 A5 JP2014012683 A5 JP 2014012683A5
Authority
JP
Japan
Prior art keywords
ige
fab
pharmaceutical composition
atopic
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013166370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014012683A (ja
Filing date
Publication date
Priority claimed from SE0101093A external-priority patent/SE0101093D0/xx
Application filed filed Critical
Publication of JP2014012683A publication Critical patent/JP2014012683A/ja
Publication of JP2014012683A5 publication Critical patent/JP2014012683A5/ja
Pending legal-status Critical Current

Links

JP2013166370A 2001-03-28 2013-08-09 アレルギーおよび喘息の治療用新規化合物 Pending JP2014012683A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101093A SE0101093D0 (sv) 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma
SE0101093-3 2001-03-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002577880A Division JP2005500992A (ja) 2001-03-28 2002-03-28 アレルギーおよび喘息の治療用新規化合物

Publications (2)

Publication Number Publication Date
JP2014012683A JP2014012683A (ja) 2014-01-23
JP2014012683A5 true JP2014012683A5 (cg-RX-API-DMAC7.html) 2015-03-05

Family

ID=20283563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002577880A Pending JP2005500992A (ja) 2001-03-28 2002-03-28 アレルギーおよび喘息の治療用新規化合物
JP2013166370A Pending JP2014012683A (ja) 2001-03-28 2013-08-09 アレルギーおよび喘息の治療用新規化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002577880A Pending JP2005500992A (ja) 2001-03-28 2002-03-28 アレルギーおよび喘息の治療用新規化合物

Country Status (7)

Country Link
US (2) US6986889B2 (cg-RX-API-DMAC7.html)
EP (1) EP1373322A1 (cg-RX-API-DMAC7.html)
JP (2) JP2005500992A (cg-RX-API-DMAC7.html)
AU (1) AU2002251624B8 (cg-RX-API-DMAC7.html)
CA (1) CA2441048C (cg-RX-API-DMAC7.html)
SE (1) SE0101093D0 (cg-RX-API-DMAC7.html)
WO (1) WO2002079257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884877B2 (en) 2001-10-03 2005-04-26 Florida State University Research Foundation, Inc. Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
US8137670B2 (en) * 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
US20240182599A1 (en) * 2022-10-07 2024-06-06 Abwiz Bio, Inc. Anti-ige antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトIgE モノクローナル抗体
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2000072879A1 (en) 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS

Similar Documents

Publication Publication Date Title
JP6457463B2 (ja) 処置方法
Kanwar et al. Pemphigus in India
KR20200070355A (ko) 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
US11976113B2 (en) Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins
JP2012504602A5 (cg-RX-API-DMAC7.html)
CA2825986C (en) Arthritis treatment
JP2018515493A5 (cg-RX-API-DMAC7.html)
オオグシフミタカ et al. Autoantibodies to IL-1α in sera from rapidly progressive idiopathic pulmonary fibrosis
US20240209097A1 (en) Treatment regimens
JP2014012683A5 (cg-RX-API-DMAC7.html)
Daeschlein et al. Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis
RU2006113701A (ru) Лечение респираторных заболеваний антителами против рецептора il-2
Mitchell et al. Anti-IgE and biologic approaches for the treatment of asthma
CN101199845B (zh) 一种稳定的抗IgE人源化单抗制剂
US20230365712A1 (en) Notch4 antibodies and uses thereof
Syabbalo Clinical Features and Management of Eosinophilic Asthma
Güvenir et al. The importance of IgE and the uses of anti-IgE
US20200055942A1 (en) Treatment regimens
Mahashur Role of Biologics in Asthma
WO2019025847A1 (en) TREATMENT DIAGRAMS
CN120513100A (zh) 一种tslp抗体治疗哮喘的方法
CN118488851A (zh) 特应性皮炎的治疗
WO2021255648A1 (en) Hyperimmune globulins for treatment of influenza a
Rokni et al. Effects of metformin on autoimmune immunoglobins and interferon-c in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial
Fick et al. Efficacy and Safety of Xolair Anti-IgE Monoclonal Antibody in Adult Asthmatics